Table 3 |
|||||
|
Association between study treatment and adverse events (of moderate or greater severity) within the first 14 days of treatment, stratified by age group |
|||||
| Adverse events |
Comparison groups |
Age < 5 years |
Age ≥ 5 years |
||
|
|
|||||
| RR (95% CI) |
p-value |
RR (95% CI) |
p-value |
||
|
|
|||||
| Anorexia |
AQ+SP vs. AL |
3.82 (1.59–9.17) |
0.003 |
1.73 (0.79–3.81) |
0.17 |
| AQ+SP vs. AS+AQ |
2.10 (1.04–4.23) |
0.04 |
1.32 (0.64–2.71) |
0.46 |
|
|
|
|||||
| Weakness |
AQ+SP vs. AL |
5.40 (1.86–15.7) |
0.002 |
3.08 (1.17–8.14) |
0.02 |
| AQ+SP vs. AS+AQ |
2.26 (1.01–5.05) |
0.04 |
1.68 (0.76–3.69) |
0.20 |
|
|
|
|||||
| Subjective fever |
AQ+SP vs. AL |
1.55 (0.78–3.10) |
0.21 |
1.78 (1.08–2.93) |
0.02 |
| AQ+SP vs. AS+AQ |
1.22 (0.64–2.31) |
0.54 |
2.80 (1.53–5.12) |
0.001 |
|
|
|
|||||
| Elevated temperature |
AL vs. AQ+SP or AS+AQ |
1.34 (0.60–3.03) |
0.47 |
3.66 (1.59–8.41) |
0.002 |
|
|
|||||
|
Maiteki-Sebuguzi et al. Malaria Journal 2008 7:106 doi:10.1186/1475-2875-7-106 |
|||||
